Eli Lilly, Lycia partner to develop new LYTAC degraders

By The Science Advisory Board staff writers

August 25, 2021 -- Lilly and Lycia Therapeutics have signed a multiyear deal to develop and commercialize new lysosomal targeting chimera (LYTAC) degraders based on Lycia's proprietary protein degradation technology.

Lycia's next-generation degradation approach targets the untapped extracellular proteome, including cell surface receptors and secreted proteins.

The platform may eventually enable the development of several therapy models, including antibodies and small molecules, potentially inhibiting many targets previously deemed intractable in numerous diseases.

The companies will use Lycia's platform to discover and develop novel degraders for up to five targets that address key unmet needs in Lilly's therapeutic focus, including immunology and pain. Lilly will be responsible for preclinical and clinical development of candidates.

Under the agreement, Lycia will receive an upfront payment of $35 million. Lycia is also eligible to receive over $1.6 billion in potential milestone payments based on the achievement of prespecified preclinical, development, and commercial milestones, as well as tiered royalties on sales.

Lilly Bio-Medicines splits into neuroscience, immunology units
Eli Lilly has divided Lilly Bio-Medicines into neuroscience and immunology business units. The company said the move will help it introduce "breakthrough...
Lilly to acquire Protomer Technologies for $1B
Eli Lilly will acquire private biotechnology firm Protomer Technologies for an estimated $1 billion.
Lilly, MiNA collaborate on saRNA research
Eli Lilly is teaming up with RNA activation therapeutics firm MiNA Therapeutics on a global research collaboration to develop drug candidates using MiNA's...
Eli Lilly gets EUA for COVID-19 mAb combo
The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to Eli Lilly for the combination of the monoclonal antibodies (mAbs)...
Lilly's mAb highly protective against COVID-19 in nursing homes
Eli Lilly's monoclonal antibody (mAb) LY-CoV555 (bamlanivimab) significantly reduced the risk of contracting COVID-19 among residents and staff of long-term...

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter